title: Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome.
abstract: Although Wnt/beta-catenin pathway activation has been implicated in mouse models of breast cancer, there is contradictory evidence regarding its importance in human breast cancer. In this study, invasive and in situ breast cancer tissue microarrays containing luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)(+)/ER(-) and basal-like breast cancers were analyzed for beta-catenin subcellular localization. We demonstrate that nuclear and cytosolic accumulation of beta-catenin, a read-out of Wnt pathway activation, was enriched in basal-like breast cancers. In contrast, membrane-associated beta-catenin was observed in all breast cancer subtypes, and its expression decreased with tumor progression. Moreover, nuclear and cytosolic localization of beta-catenin was associated with other markers of the basal-like phenotype, including nuclear hormone receptor and HER2 negativity, cytokeratin 5/6 and vimentin expression, and stem cell enrichment. Importantly, this subcellular localization of beta-catenin was associated with a poor outcome and is more frequently observed in tumors from black patients. In addition, beta-catenin accumulation was more often observed in basal-like in situ carcinomas than other in situ subtypes, suggesting that activation of this pathway might be an early event in basal-like tumor development. Collectively, these data indicate that Wnt/beta-catenin activation is an important feature of basal-like breast cancers and is predictive of worse overall survival, suggesting that it may be an attractive pharmacological target for this aggressive breast cancer subtype.
authors.affiliation: University of Chicago, Department of Medicine, Chicago, IL 60637, USA.
authors.forename: Andrey I
authors.initials: AI
authors.lastname: Khramtsov
authors.forename: Galina F
authors.initials: GF
authors.lastname: Khramtsova
authors.forename: Maria
authors.initials: M
authors.lastname: Tretiakova
authors.forename: Dezheng
authors.initials: D
authors.lastname: Huo
authors.forename: Olufunmilayo I
authors.initials: OI
authors.lastname: Olopade
authors.forename: Kathleen H
authors.initials: KH
authors.lastname: Goss
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology*; D005260:Female; D006801:Humans; D051379:Mice; D046228:Microarray Analysis; D008875:Middle Aged; D018295:Neoplasms, Basal Cell / Q000378:metabolism* / Q000473:pathology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology*; D015996:Survival Rate; D051153:Wnt Proteins / Q000378:metabolism*; D051176:beta Catenin / Q000378:metabolism*
chemical_list: D015415:Biomarkers; D018719:Erb-b2 Receptor Tyrosine Kinases; D051153:Wnt Proteins; D051176:beta Catenin
references.citation: Nat Cell Biol. 2001 Sep;3(9):793-801
references.pmid: 11533658
references.citation: J Mol Histol. 2007 May;38(2):113-21
references.pmid: 17318343
references.citation: J Cell Sci. 2007 Feb 1;120(Pt 3):468-77
references.pmid: 17227796
references.citation: Am J Pathol. 2002 Sep;161(3):1087-97
references.pmid: 12213737
references.citation: Cancer. 2007 May 1;109(9):1721-8
references.pmid: 17387718
references.citation: Carcinogenesis. 2000 Nov;21(11):1935-40
references.pmid: 11062151
references.citation: J Pathol. 2001 Apr;193(4):433-41
references.pmid: 11276001
references.citation: Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4262-6
references.pmid: 10759547
references.citation: Cell. 1987 Aug 14;50(4):649-57
references.pmid: 3111720
references.citation: J Pathol. 2007 Mar;211(4):389-98
references.pmid: 17212342
references.citation: Br J Cancer. 2002 Nov 18;87(11):1281-6
references.pmid: 12439718
references.citation: Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):618-23
references.pmid: 17202265
references.citation: Cell. 1988 Nov 18;55(4):619-25
references.pmid: 3180222
references.citation: Breast Cancer Res. 2008;10(3):R53
references.pmid: 18559090
references.citation: Cancer Cell. 2004 Jan;5(1):91-102
references.pmid: 14749129
references.citation: Biometrics. 1994 Dec;50(4):933-44
references.pmid: 7787006
references.citation: Cell. 2006 Nov 3;127(3):469-80
references.pmid: 17081971
references.citation: Histopathology. 2000 Apr;36(4):313-25
references.pmid: 10759945
references.citation: Breast Cancer Res Treat. 2005 Apr;90(3):249-56
references.pmid: 15830138
references.citation: Cancer Res. 2003 May 15;63(10):2658-64
references.pmid: 12750294
references.citation: Cancer Res. 2008 Feb 15;68(4):989-97
references.pmid: 18281472
references.citation: Nat Med. 1998 Jul;4(7):844-7
references.pmid: 9662379
references.citation: Clin Cancer Res. 2007 Apr 15;13(8):2329-34
references.pmid: 17438091
references.citation: Nat Clin Pract Oncol. 2008 Mar;5(3):149-59
references.pmid: 18212769
references.citation: Cancer. 2004 May 15;100(10):2084-92
references.pmid: 15139049
references.citation: Nature. 2000 Aug 17;406(6797):747-52
references.pmid: 10963602
references.citation: Cells Tissues Organs. 2007;185(1-3):191-203
references.pmid: 17587825
references.citation: J Cancer Res Clin Oncol. 1999;125(5):297-304
references.pmid: 10359135
references.citation: J Pathol. 2002 Feb;196(2):145-53
references.pmid: 11793365
references.citation: Mod Pathol. 2006 May;19(5):617-21
references.pmid: 16528377
references.citation: Cancer Res. 2006 May 15;66(10):5487-94
references.pmid: 16707478
references.citation: Clin Cancer Res. 2008 Jul 1;14(13):4038-44
references.pmid: 18593979
references.citation: Cancer Res. 1990 Nov 1;50(21):7057-61
references.pmid: 2208173
references.citation: Virchows Arch. 1997 Sep;431(3):167-72
references.pmid: 9334837
references.citation: J Mammary Gland Biol Neoplasia. 2003 Apr;8(2):145-58
references.pmid: 14635791
references.citation: Histol Histopathol. 2009 Mar;24(3):385-98
references.pmid: 19130408
references.citation: J Cell Sci. 2005 Aug 15;118(Pt 16):3585-94
references.pmid: 16105882
references.citation: J Clin Pathol. 1993 Feb;46(2):189-90
references.pmid: 8459046
references.citation: PLoS One. 2009;4(3):e4968
references.pmid: 19319191
references.citation: Eur J Surg Oncol. 2001 Feb;27(1):31-6
references.pmid: 11237489
references.citation: Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12682-7
references.pmid: 15314234
references.citation: Cancer Res. 2009 May 15;69(10):4116-24
references.pmid: 19435916
references.citation: J Clin Oncol. 2007 Jan 1;25(1):118-45
references.pmid: 17159189
references.citation: J Pathol. 1998 Jul;185(3):262-6
references.pmid: 9771479
references.citation: JAMA. 2006 Jun 7;295(21):2492-502
references.pmid: 16757721
references.citation: Br J Cancer. 1999 Jun;80(7):1046-51
references.pmid: 10362114
references.citation: Am J Pathol. 1998 Jan;152(1):75-82
references.pmid: 9422525
references.citation: Mod Pathol. 2006 Nov;19(11):1506-11
references.pmid: 16941011
references.citation: BMC Genomics. 2006 Apr 27;7:96
references.pmid: 16643655